Towards home-based treatment for acute promyelocytic leukaemia, with caution

Affiliations

¹ Department of Biomedicine and Prevention, University Tor Vergata, Rome 00133, Italy. Electronic address: francesco.lo.coco@uniroma2.it.
² Department of Biomedicine and Prevention, University Tor Vergata, Rome 00133, Italy.

Comment

Francesco Lo-Coco et al. Lancet Oncol. 2018 Jul.

. 2018 Jul;19(7):846-847.

doi: 10.1016/S1470-2045(18)30355-3. Epub 2018 Jun 5.

¹ Department of Biomedicine and Prevention, University Tor Vergata, Rome 00133, Italy. Electronic address: francesco.lo.coco@uniroma2.it.
² Department of Biomedicine and Prevention, University Tor Vergata, Rome 00133, Italy.

No abstract available

Comment on

Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, Shao ZH, Ren HY, Hu JD, Xu KL, Wang JW, Song YP, Fang MY, Li J, Yan XY, Huang XJ. Zhu HH, et al. Lancet Oncol. 2018 Jul;19(7):871-879. doi: 10.1016/S1470-2045(18)30295-X. Epub 2018 Jun 5. Lancet Oncol. 2018. PMID: 29884593 Clinical Trial.